A Study of SPI-62 for Cushing's Syndrome

Share

Full Title

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushings Syndrome

Purpose

Cushing’s syndrome occurs when the adrenal glands produce too much of the stress hormone known as cortisol. In this study, researchers are assessing the safety of the drug SPI-62 in people with adrenocorticotropic hormone (ACTH)-dependent Cushing’s syndrome.

SPI-62 may help reduce Cushing’s syndrome symptoms in these patients because it can lower the amount of cortisol inside cells in different parts of the body. It blocks an enzyme in cells that changes inactive cortisol into active cortisol, decreasing the amount of cortisol in the body. SPI-62 is taken orally (by mouth).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have ACTH-dependent Cushing’s syndrome.
  • Patients must also have at least one Cushing’s-related diagnosis, such as diabetes, dyslipidemia (such as high blood cholesterol), hypertension (high blood pressure), and/or osteopenia (low bone density).
  • This study is for people age 18 and older.

Contact

For more information and to ask about eligibility for this study, please contact the office of Dr. Eliza Geer at 646-608-3797.

Protocol

22-337

Phase

Phase II (phase 2)

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator

Monica Girotra

Diseases

ClinicalTrials.gov ID

NCT05307328